|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
82,860,000 |
Market
Cap: |
159.09(M) |
Last
Volume: |
326,170 |
Avg
Vol: |
1,023,056 |
52
Week Range: |
$0.53 - $2.95 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Compugen is a clinical-stage therapeutic discovery and development company utilizing its predictive computational discovery capabilities to identify drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Co.'s immuno-oncology pipeline consists of four clinical stage programs, COM701, which is an anti-PVRIG antibody, for the treatment of solid tumors; COM902, which is a therapeutic antibody targeting TIGIT; Bapotulimab, which is an antibody targeting ILDR2; and AZD2936, which is an anti-TIGIT/PD-1 bispecific antibody with a TIGIT component that is derived from Co.'s COM902 program.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|